T2 Biosystems Expands Intellectual Property Portfolio Covering T2MR® Direct Detection Diagnostic Platform

LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued two patents adding depth and breadth to the protection of the Company’s T2MR® platform and the T2Dx® detection system. Both patents are part of the growing intellectual property estate protecting T2 Bio’s breakthrough detection capabilities, including the Company’s flagship T2Candida® multiplex test panel that detects the presence of species-specific Candida directly from whole blood in approximately three hours without the requirement for blood culturing.

Help employers find you! Check out all the jobs and post your resume.